ストックスクリーナーアプリを入手
2.02
2.88%
-0.06
前日終値:
$2.08
開ける：
$2.03
24時間の取引高:
123.85K
Relative Volume:
0.33
時価総額：
$39.37M
収益：
-
当期純損益:
$-40.94M
株価収益率:
-0.526
EPS:
-3.84
ネットキャッシュフロー:
$-22.97M
1週間 パフォーマンス:
+12.85%
1か月 パフォーマンス:
+33.77%
6か月 パフォーマンス:
-69.62%
1年 パフォーマンス:
-71.47%
1日の値動き範囲:
$1.945
$2.0599
1週間の範囲:
$1.7318
$2.20
52週間の値動き範囲:
$1.11
$17.88
Annovis Bio Inc Stock (ANVS) Company Profile
名前
Annovis Bio Inc
セクター
電話
484-875-3192
住所
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
ANVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.02 | 32.93M | 0 | -40.94M | -22.97M | -3.84 |
|
ONC
Beigene Ltd Adr
|
242.17 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.61 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.33 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.40 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.77 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-10 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2024-10-25 | アップグレード | Maxim Group | Hold → Buy |
| 2023-12-29 | 開始されました | Canaccord Genuity | Buy |
| 2021-07-07 | 繰り返されました | Maxim Group | Buy |
Annovis Bio Inc (ANVS) 最新ニュース
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN
Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress - MyChesCo
Canaccord Genuity Group Issues Pessimistic Forecast for Annovis Bio (NYSE:ANVS) Stock Price - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Canaccord cuts Annovis Bio stock target to $17; keeps Buy rating - Investing.com Australia
Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Annovis Bio (ANVS) Price Target Reduced by Canaccord Genuity | ANVS Stock News - GuruFocus
Annovis Bio (ANVS) Target Price Lowered as Phase 3 Alzheimer's T - GuruFocus
Annovis Bio Launches Phase 3 Alzheimer’s Trial, Expands Research Efforts - citybuzz -
Annovis Bio Appoints New Principal Financial Officer - TipRanks
Annovis Provides Corporate Updates And Reports First Quarter 2025 Financial Results - marketscreener.com
Annovis Bio Inc. Provides Corporate Updates and Q1 2025 Financial Results, Initiates Pivotal Phase 3 Clinical Trial for Alzheimer’s Disease - Nasdaq
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results - GlobeNewswire
Annovis Bio's New Phase 3 Alzheimer's Drug Trial Targets Both Symptoms and Disease Modification - Stock Titan
Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Monday - Defense World
Annovis Bio Appoints Hui Liu as Director of Biostatistics - MSN
Annovis Bio Strengthens Research Team with Appointment of Hui Liu as Director of Biostatistics - citybuzz -
Annovis Bio hires new director of biostatistics amid AD trial - Investing.com
Annovis Bio Appoints Hui Liu As Director Of Biostatistics - marketscreener.com
Annovis Bio Bolsters Alzheimer's Phase 3 Trial Team: Statistics Expert Joins at Critical Stage - Stock Titan
LAWSUITS FILED AGAINST SLQT, ANVS and VIEWJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of “Buy” from Analysts - Defense World
Head-To-Head Survey: Eterna Therapeutics (NASDAQ:ERNA) and Annovis Bio (NYSE:ANVS) - Defense World
Annovis Bio stock plunges to 52-week low of $1.14 By Investing.com - Investing.com Canada
Annovis Bio stock plunges to 52-week low of $1.14 - Investing.com
Buntanetap shows early potential for Parkinson’s-related dementia - The Pharma Letter
Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com
Buntanetap for Parkinson’s disease - Parkinson's News Today
Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MSN
Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com - Investing.com South Africa
Annovis Bio stock hits 52-week low at $1.52 amid sharp decline - Investing.com India
Annovis Bio Receives Non-Compliance Notice from NYSE - MSN
Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 - MSN
Annovis Bio faces NYSE delisting over market cap, equity shortfall By Investing.com - Investing.com South Africa
Annovis Bio Gets NYSE Noncompliance Notice - MarketScreener
Annovis Bio Faces NYSE Non-Compliance Notice - TipRanks
Annovis Bio faces NYSE delisting over market cap, equity shortfall - Investing.com
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - GlobeNewswire
NYSE Warning: Annovis Bio Must Submit 45-Day Survival Plan as Market Cap Plunges - Stock Titan
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - GlobeNewswire
Stocks In Spotlight: ANVS, PTN, AVIR, IRWD, FGEN, ACAD - RTTNews
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN
Agitation in Alzheimer's Disease Market: Analysis - openPR.com
Annovis Bio Inc. to Present Key Findings at AD/PD™ 2025 Conference in Vienna on Alzheimer's and Parkinson's Treatments - Nasdaq
Annovis Bio Inc (ANVS) 財務データ
収益
当期純利益
現金流量
EPS
13.67%
大文字化:
|
ボリューム (24 時間):